Cramer: Hewlett's Back
Health Care: Drugs
XOMA Corp (XOMA: NASDAQ)
$4.04 0.08 | 2.02%
05/23/13 - 11:56 AM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -71.06M | -32.74M | -68.76M | 550.00K |
| Operating Gains/Losses | 0.00 | 1.02M | 362.00K | 2.51M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 4.06M | 8.53M | -13.63M | 9.46M |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 4.48M | -2.14M | 2.65M | -2.84M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | -3.44M | -13.84M | 12.88M | -13.68M |
| Other Non-Cash Items | 19.26M | 5.86M | 8.04M | 4.33M |
| Net Cash From Continuing Operations | -40.76M | -29.06M | -52.54M | 7.44M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -40.76M | -29.06M | -52.54M | 7.44M |
| Sale of Property, Plant & Equipment | 463.00K | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -2.51M | -3.30M | -339.00K | -270.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 9.54M |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -42.02M | -3.30M | -339.00K | 10.58M |
| Issuance of Debt | 4.43M | 28.84M | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 77.49M | 15.14M | 70.77M | 49.32M |
| Repayment of Long-Term Debt | -2.14M | 0.00 | -4.50M | -52.94M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 79.78M | 43.98M | 66.27M | -3.61M |
| Effect of Exchange Rate Changes | 0.00 | -573.00K | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -3.00M | 11.04M | 13.40M | 14.40M |
Portfolios with XOMA
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks With Big Insider Buy...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- Usersuresh45
- Userdd
- ContributorStocks Under-$10 Setting Up...
- Userconsidering
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
Latest XOMA Headlines from TheStreet
- XOMA Highlights Recent Achievements And Reports Financial Results For First Quarter 2013 05.08.13 | 04:05 pm
- XOMA To Present At Credit Suisse 2013 Antibody Day 05.06.13 | 02:05 pm
- XOMA To Announce First Quarter 2013 Financial Results And Host Webcast On May 8 04.25.13 | 08:04 am
- XOMA Announces Clinical Study Investigating Gevokizumab In Patients With Non-Infectious Anterior Scleritis Has Opened For Enrollment At The National Eye Institute 04.10.13 | 08:04 am
- 8 Stocks Under $5 Seeing Institutional And Insider Buying 04.02.13 | 03:04 pm
- 7 Biotechnology Stocks With Insider Buying Activity 03.20.13 | 10:03 am
- XOMA Appoints Tom Klein To Newly Created Position Of Chief Commercial Officer 03.18.13 | 01:03 pm
- EZChip: My Struggling Core Holding May See Better Days 03.16.13 | 07:03 am
- XOMA Reports 2012 Operational Highlights And Fourth Quarter And Full-Year Financial Results 03.12.13 | 04:03 pm
- XOMA Announces Fourth Quarter And Full-Year Financial Results Conference Call 03.04.13 | 01:03 pm
Press Releases for XOMA
- CMC Biologics Acquires XOMA's Bay Area Manufacturing Facility - PR Newswire 07.31.12 | 08:07 am
Partner Headlines for XOMA
- Positive Data on XOMA Candidate - Analyst Blog - Zacks 11.26.12 | 06:11 pm
- UPDATE: Credit Suisse Initiates XOMA Corporation at Outperform on Upside Potential - Benzinga 11.13.12 | 01:11 pm
- XOMA Announces Servier Has Initiated Phase 3 Gevokizumab Trial in Patients With Behcet's Uveitis - Benzinga 09.27.12 | 01:09 pm
- Orphan Status for XOMA's Candidate - Analyst Blog - NASDAQ 08.23.12 | 07:08 pm
- Loss at XOMA Wider Than Expected - Analyst Blog - Zacks 03.20.12 | 10:03 am
- Noteworthy Institutional 5% Ownership Filings Last Week - Seeking Alpha 03.19.12 | 09:03 am
- Xoma's New Plans Bring Hesitant Hope - Seeking Alpha 01.25.12 | 09:01 am
- XOMA Will Move Its Corporate Domicile to Delaware - Benzinga 12.30.11 | 04:12 pm
- XOMA CEO Engle Resigns - Benzinga 08.31.11 | 04:08 pm
- 15 Stocks Posting Big Jumps This Week - Seeking Alpha 06.30.11 | 08:06 am
